Press Release: Medtronic Announces Cash Dividend For Third Quarter Of Fiscal Year 2026

GALWAY, Ireland, Dec. 4, 2025 /PRNewswire/ — The board of directors of Medtronic plc on Thursday, December 4, 2025, approved the company's cash dividend for the third quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2025. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 48 consecutive years. The dividend is payable on January 16, 2026, to shareholders of record at the close of business on December 26, 2025.

About Medtronic

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic , visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:

Jane Di Leo

Public Relations

jane.e.dileo@medtronic.com

Ryan Weispfenning

Investor Relations

+1-763-505-4626

View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-announces-cash-dividend-for-third-quarter-of-fiscal-year-2026-302633588.html

SOURCE Medtronic plc

WASHINGTON (dpa-AFX) - Medtronic (MDT) announced that it has received FDA clearance for its Hugo robotic-assisted surgery (RAS) system in urologic procedures, marking a significant milestone in its surgical innovation portfolio. The Hugo system's modular design, integration with the Touch Surgery digital ecosystem, and Medtronic's unique ability to serve across open, laparoscopic, and robotic modalities position the company to expand its presence in the fast-growing robotic surgery market.

The clearance enhances Medtronic's competitive edge, supports adoption of minimally invasive care, and strengthens long-term growth opportunities. With differentiated technology and training capabilities, Medtronic is well-placed to drive value creation for healthcare providers and shareholders alike.

Outside the U.S., the Hugo RAS system has been used in tens of thousands of urologic, gynecologic, and general surgery procedures in more than 30 countries across 5 continents. Medtronic intends to expand the Hugo RAS system's use in the U.S. to additional surgical specialties over time, with indications for general and gynecologic surgical procedures expected to follow the initial urology clearance.

For More Such Health News, visit rttnews.com.

Copyright(c) 2025 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX

DUBLIN (dpa-AFX) - Medtronic (MDT) has begun the full U.S. rollout of the MiniMed 780G insulin delivery system integrated with Abbott's Instinct sensor, following FDA clearance earlier this year.

The system is now shipping nationwide, marking a major expansion in automated diabetes technology.

The Instinct sensor, built on Abbott's latest CGM platform, is the smallest and thinnest sensor of its kind and can be worn for up to 15 days. When paired with the 780G system, it delivers continuous real-time glucose readings that allow the pump's algorithm to adjust insulin every five minutes, reducing highs and lows and easing daily management. Early pilot feedback from patients and clinicians has been strongly positive, with reports of improved time in range and a smoother user experience.

Medtronic said the Instinct launch adds to its expanding sensor portfolio, alongside Simplera Sync and Guardian 4, giving users more tailored options. The company emphasized its goal of building a flexible, smart dosing ecosystem that offers greater predictability and freedom for people with diabetes.

MDT currently trades at $102.74, or 0.59% lower on the NYSE.

Copyright(c) 2025 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX